Glucagon, from past to present: a century of intensive research and controversies

Autor: André J, Scheen, Pierre J, Lefèbvre

Publikováno v: The Lancet Diabetes & Endocrinology. 11:129-138

2022 corresponds to the 100th anniversary of the discovery of glucagon. This TimeCapsule aims to recall the main steps leading to the discovery, characterisation, and clinical importance of the so-called second pancreatic hormone. We describe the ear

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3dc8149f0043c3d8ed78eddb0933a54
https://doi.org/10.1016/s2213-8587(22)00349-7

The Discovery of Glucagon and Glucagon-Related Peptides

Autor: Pierre J. Lefèbvre

Publikováno v: Frontiers in Diabetes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4861b36c2e8be9363f10bf936009b609
https://doi.org/10.1159/000506555

Pancreatic Hormones

Autor: Pierre De Meyts, Pierre J. Lefèbvre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5e4ab0cb62bbe0e6dead717b82bf3404
https://doi.org/10.1016/b978-0-12-813814-4.00017-1

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Autor: John A, Dormandy, Bernard, Charbonnel, David J A, Eckland, Erland, Erdmann, Massimo, Massi-Benedetti, Ian K, Moules, Allan M, Skene, Meng H, Tan, Pierre J, Lefèbvre, Gordon D, Murray, Eberhard, Standl, Robert G, Wilcox, Lars, Wilhelmsen, John, Betteridge, Kåre, Birkeland, Alain, Golay, Robert J, Heine, László, Korányi, Markku, Laakso, Marián, Mokán, Antanas, Norkus, Valdis, Pirags, Toomas, Podar, André, Scheen, Werner, Scherbaum, Guntram, Schernthaner, Ole, Schmitz, Jan, Skrha, Ulf, Smith, Jan, Taton, T D M, Williams

Publikováno v: Dormandy, J A, Charbonnel, B, Eckland, D J, Erdmann, E, Massi-Benedetti, M, Moules, I K, Skene, A M, Tan, M H, Lefebvre, P J, Murray, G D, Standl, E & Wilcox, R G 2005, ' Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial ', Lancet, vol. 366, no. 9493, pp. 1279-1289 . https://doi.org/10.1016/S0140-6736(05)67528-9
Dormandy, J A, Charbonnel, B, Eckland, D J, Erdmann, E, Massi-Benedetti, M, Moules, I K, Skene, A M, Tan, M H, Lefebvre, P J, Murray, G D, Standl, E, Wilcox, R G, Wilhelmsen, L, Betteridge, J, Birkeland, K, Golay, A, Heine, R J, Koranyi, L, Laakso, M, Mokan, M, Norkus, A, Pirags, V, Podar, T, Scheen, A, Scherbaum, W, Schernthaner, G, Schmitz, O, Skrha, J, Smith, U & Taton, J 2005, ' Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial ', The Lancet, vol. 366(9493), pp. 1279-1289 .
Lancet, 366(9493), 1279-1289. Elsevier Limited

Patients with type 2 diabetes are at high risk of fatal and non-fatal myocardial infarction and stroke. There is indirect evidence that agonists of peroxisome proliferator-activated receptor gamma (PPAR gamma) could reduce macrovascular complications

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c2b925ba490c64f541b2f444a756d92
https://doi.org/10.1016/s0140-6736(05)67528-9

The Pathology of the Endocrine Pancreas in Diabetes

Autor: Pierre J. Lefebvre, Daniel G. Pipeleers

Diabetes mellitus represents one of the most frequent and serious clinical syn­ dromes in contemporary medicine. Since the end of the nineteenth century, the endocrine pancreas has been implicated in the pathogenesis of this disease. Several patholo